QUASENSE- levonorgestrel and ethinyl estradiol United States - English - NLM (National Library of Medicine)

quasense- levonorgestrel and ethinyl estradiol

actavis pharma, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - quasense® (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. do not prescribe quasense to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1) ]. have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1) ]. have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1) ]. have cerebrovascular disease [see warnings and precautions (5.1) ]. have coronary artery disease [see warnings and precautions (5.1) ]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1) ]. have uncontrolled hypertension [see warnings

INTROVALE- levonorgestrel and ethinyl estradiol United States - English - NLM (National Library of Medicine)

introvale- levonorgestrel and ethinyl estradiol

sandoz inc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - introvaletm (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. do not prescribe introvaletm (levonorgestrel and ethinyl estradiol tablets) to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rythym diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] have

ALTAVERA- levonorgestrel and ethinyl estradiol United States - English - NLM (National Library of Medicine)

altavera- levonorgestrel and ethinyl estradiol

sandoz inc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and the iud, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table 1: percentage of women experiencing an unintended pregnancy during the first year of use of a contraceptive method method perfect use typical use levonorgestrel implants 0.05 0.05 male sterilization 0.1 0.15 female sterilization 0.5 0.5 depo-provera® (injectable progestogen) 0.3 0.3 oral contraceptives 5 combined 0.1 na progestin only 0.5 na iud progesterone 1.5 2 copper t 380a 0.6 0.8 condom (male) without spermicide 3 14 (female) without spermicide 5 21 cervical cap nulliparous women 9 20 par

MARLISSA- levonorgestrel and ethinyl estradiol kit United States - English - NLM (National Library of Medicine)

marlissa- levonorgestrel and ethinyl estradiol kit

glenmark pharmaceuticals inc., usa - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - marlissa® (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. marlissa® (levonorgestrel and ethinyl estradiol tablets) is contraindicated in females who are known to have the following conditions:                                                               marlissa® (mĀr-lis-sĂ)                              (levonorgestrel and ethinyl estradiol tablets, usp 0.15 mg/0.03 mg) important information about taking marlissa® (levonorgestrel and ethinyl estradiol tablets) before you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets): when should i start taking marlissa® (levonorgestrel and ethinyl estradiol tablets)? if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you have not used a hormonal birth control method before: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from another birth control pill: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and previously used a vaginal ring: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and previously used a transdermal patch: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from a progestin-only method such as an implant or injection: if you start taking marlissa® (levonorgestrel and ethinyl estradiol tablets) and you are switching from an intrauterine device or system (iud or ius): keep a calendar to track your period: if this is the first time you are taking birth control pills, read, “when should i start taking marlissa® (levonorgestrel and ethinyl estradiol tablets)? ” above. follow these instructions for either a sunday start or a day 1 start . instructions for using your marlissa® (levonorgestrel and ethinyl estradiol tablets) pill dispenser: sunday start: you will use a sunday start if your healthcare provider told you to take your first pill on a sunday. day 1 start: you will use a day 1 start if your doctor told you to take your first pill (day 1) on the first day of your period . what should i do if i miss any marlissa® (levonorgestrel and ethinyl estradiol tablets) pills? if you miss 1 pill in weeks 1, 2, or 3, follow these steps: if you miss 2 pills in week 1 or week 2 of your pack, follow these steps: if you miss 2 pills in a row in week 3, or you miss 3 or more pills in a row during weeks 1, 2, or 3 of the pack, follow these steps: if you have any questions or are unsure about the information in this leaflet, call your healthcare provider. this patient information and instructions for use have been approved by the u.s. food and drug administration. manufactured by: glenmark pharmaceuticals limited colvale-bardez, goa 403513, india manufactured for: glenmark pharmaceuticals inc., usa mahwah, nj 07430 questions? 1 (888) 721-7115 www.glenmarkpharma-us.com june 2022

PORTIA- levonorgestrel and ethinyl estradiol kit United States - English - NLM (National Library of Medicine)

portia- levonorgestrel and ethinyl estradiol kit

teva pharmaceuticals usa, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - portia (levonorgestrel and ethinyl estradiol tablets usp) is indicated for use by females of reproductive potential to prevent pregnancy. portia (levonorgestrel and ethinyl estradiol tablets usp) is contraindicated in females who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: - smoke, if over age 35 [see boxed warning and warnings (1) ]. - have current or history of deep vein thrombosis or pulmonary embolism [see warnings (1) ]. - have cerebrovascular disease [see warnings (1) ]. - have coronary artery disease [see warnings (1) ]. - have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings (1) ]. - have inherited or acquired hypercoagulopathies [see warnings (1) ]. - have uncontrolled hypertension or hypertension with vascular disease [see warnings (3) ]. - have diabetes mellitus and are over ag

ASHLYNA- levonorgestrel and ethinyl estradiol and ethinyl estradiol kit United States - English - NLM (National Library of Medicine)

ashlyna- levonorgestrel and ethinyl estradiol and ethinyl estradiol kit

glenmark pharmaceuticals inc., usa - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - ashlyna is indicated for use by females of reproductive potential to prevent pregnancy. ashlyna is contraindicated in females who are known to have or develop the following conditions: risk summary there is no use for contraception in pregnancy; therefore, levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets should be discontinued during pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to cocs before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. risk summary contraceptive hormones and/or metabolites are present in human milk. cocs can reduce milk production in breastfeeding females. this reduction can occur at any time but is less likely to occur once breastf

INTROVALE- levonorgestrel and ethinyl estradiol kit United States - English - NLM (National Library of Medicine)

introvale- levonorgestrel and ethinyl estradiol kit

xiromed, llc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - introvale®  (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. introvale is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1) ]. have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1) ]. have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1) ]. have cerebrovascular disease [see warnings and precautions (5.1) ]. have coronary artery disease [see warnings and precautions (5.1) ]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1) ]. have uncontrolled hypertension [see warnings and precautions (5.4) ]. have d

VIENVA- levonorgestrel and ethinyl estradiol kit United States - English - NLM (National Library of Medicine)

vienva- levonorgestrel and ethinyl estradiol kit

xiromed, llc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.1 mg - vienva (levonorgestrel and ethinyl estradiol tablets, usp) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and norplant® system, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year3 method (1) typical use1 (2) perfect use2 (3) (4) chance 4 85 85 spermicides 5 26 6 40 periodic abstinence 25 63 calendar 9 ovulation method 3 sympto-thermal 6 2 post-ovulation 1 cap7 parous women 40 26 42 nulliparous women 20 9 56 sponge parous women 40 20 42 nulliparous women 20 9 56 diaphragm7 20 6 56 withdrawal 19 4 cond

Florina 28 Tablet Kenya - English - Pharmacy and Poisons Board

florina 28 tablet

questa care inc., c/o surgilinks ltd 8, the green, suite 12338, dover, de 19901, usa - levonorgestrel and ethinylestradiol tablets bp… - tablet - levonorgestrel bp 0.15mg, ethinylestradiol bp… - levonorgestrel and ethinylestradiol

NORLEVO Israel - English - Ministry of Health

norlevo

cts ltd - levonorgestrel - tablets - levonorgestrel 1.5 mg - levonorgestrel - levonorgestrel - emergency contraceptive.